Newsletter Subscription

Enter Name and Email

08 August 2014 - Adrian is Principal Investigator of a new grant from the MJFF

The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Neurolixis Inc co-founder and Chief Scientific Officer, an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system diseases including Parkinson's disease and Rett syndrome. The supplementary grant will allow Neurolixis to further characterise its exceptionally-selective and efficacious serotonin 5-HT1A receptor agonists in models of dyskinesia. This is a common side-effect experienced by many Parkinson's disease patients treated with the antiparkinsonian agent, levodopa. If the new studies are successful, Neurolixis aims to take its clinical candidate, NLX-112, into proof-of-concept Phase 2 trials. 

Read the full press announcement:  pdf_symbol.